ESMO 2020 Highlights on 1st line lorlatinib for ALK+ NSCLC: The CROWN Study
Benjamin Solomon reports on key results from ESMO Virtual Congress 2020 on LBA2: Lorlatinib vs Crizotinib in the First-line Treatment of Patients (pts) with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC): Results of the Phase 3 CROWN Study
Produced by ESMO, https://oncologypro.esmo.org
![Frightened Rabbit - Backyard Skulls [Official Video]](https://images.videosashka.com/watch/bx7dF89a3z4)
